Implementing VTE Prevention in Ambulatory Cancer Care

assess effectiveness of a , compared with usual care, to assess

The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question[s] it aims to answer are:

Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).

Participant clinicians will be asked to

• receive education about VTE prevention recommendations
• carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.

Study Overview

• Status: Enrolling by invitation
• Conditions: Neoplasms; Venous Thromboembolism
• Intervention / Treatment: Other: Clinical program

• Study Type: Interventional
• Enrollment (Estimated): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Vermont
    • Burlington, Vermont, United States, 05405
      • Vermont Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Clinicians: practicing oncologist at study clinic site (UVMMC)
• Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician

Exclusion Criteria:

• none

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Clinical program	Other: Clinical program; Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Documented VTE risk assessment	Proportion of new patients who have documented VTE risk assessment	30 days after new patient appointment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Appropriate thromboprophylaxis	Proportion of identified high-risk patients with prescription for thromboprophylaxis and low-risk patients without thromboprophylaxis	30 days after new patient appointment

Collaborators and Investigators

• Sponsor: University of Vermont
• Investigators: Principal Investigator: Karlyn Martin, MD, University of Vermont

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2025
• Primary Completion (Estimated): April 30, 2026
• Study Completion (Estimated): July 30, 2026

Study Registration Dates

• First Submitted: December 5, 2025
• First Submitted That Met QC Criteria: December 5, 2025
• First Posted (Actual): December 18, 2025

Study Record Updates

• Last Update Posted (Actual): December 18, 2025
• Last Update Submitted That Met QC Criteria: December 5, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Embolism and Thrombosis; Thromboembolism; Neoplasms; Venous Thromboembolism
• Other Study ID Numbers: FP00005110

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No